Pcn83 - The Use of Obinutuzumab in Treatment of Refractory and Relapsing Follicular Lymphoma

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.165
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pcn133 - The Societal Impact of Obinutuzumab in the First Line Treatment of Patients With Follicular Lymphoma in Germany

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Anti-Tumor Activity of Obinutuzumab and Rituximab in a Follicular Lymphoma 3D Model

Blood Cancer Journal
OncologyHematology
2013English

Management of Patients With Follicular Lymphoma Treated First Line With Obinutuzumab

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2019English

The Immunologic Doublet of Lenalidomide Plus Obinutuzumab Is Highly Active in Relapsed/Refractory Follicular Lymphoma, Results of a Phase I/Ii Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Efficacy and Safety of Obinutuzumab + Lenalidomide + Atezolizumab in Patients With Relapsed or Refractory Follicular Lymphoma: Primary Analysis of a Phase 1b/2 Trial

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Pcn141 - Cost-Effectiveness Analysis of Obinutuzumab for the Treatment of Patients With Previously Untreated Advanced Follicular Lymphoma in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Ongoing Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Polatuzumab Vedotin (Pola) + Obinutuzumab (G) + Lenalidomide (Len) in Patients (Pts) With Relapsed/Refractory (R/R) Follicular Lymphoma (Fl): Phase Ib/Ii Interim Analysis

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Treatment of Relapse and Refractory Hodgkin Lymphoma

Oncogematologiya
OncologyHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy